spacer
home > ebr > spring 2002 > a new technology for biopharmaceutical analyses - microfluidic-based lab-on-a-chip
PUBLICATIONS
European Biopharmaceutical Review

A New Technology for Biopharmaceutical Analyses - Microfluidic-Based Lab-on-a-Chip

Although the term 'lab-on-a-chip' is relatively new, the concept of applying chip technology to miniaturise analytical instruments is not. Its roots can be traced back to 1975 when the first attempts were made to use chip technology to miniaturise analytical instruments such as gas chromatographs. Technical problems prevented commercial success of the initial attempts. In recent years, however, the development of the new field of microfluidics has established itself as an important research area and is starting to appear in commercial products. There is great interest within the pharmaceutical industry in lab-on-a-chip devices because they promise to speed up the discovery process by allowing researchers to perform more analyses faster, more accurately and reproducibly whilst using much smaller sample volumes than is possible with conventional technology.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Owen, Marketing Manager at Agilent Technologies, Germany

Dr Anthony Owen holds a degree in Chemistry and a doctorate in Physical Organic Chemistry from the University of Manchester Institute of Science and Technology. He briefly worked as a Research Chemist for Associated Octel in Ellesmere Port, UK, before joining Agilent Technologies (formerly Hewlett-Packard) in Vienna, Austria in 1979.
Since 1984 Anthony has been based in Waldbronn, Germany - firstly as Product Manager for UV-Visible spectroscopy, and since 2001 as Marketing Manager for the lab-on-a-chip products.

spacer
Dr Anthony Owen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement